$12.20
4.69% day before yesterday
Nasdaq, May 23, 10:00 pm CET
ISIN
IL0011280240
Symbol
ARCT
Sector
Industry

Arcturus Therapeutics Ltd Stock price

$12.20
-0.45 3.56% 1M
-5.38 30.60% 6M
-4.77 28.11% YTD
-19.01 60.91% 1Y
-5.87 32.48% 3Y
-46.07 79.06% 5Y
-33.30 73.19% 10Y
Nasdaq, Closing price Fri, May 23 2025
-0.60 4.69%
ISIN
IL0011280240
Symbol
ARCT
Sector
Industry

Key metrics

Market capitalization $330.87m
Enterprise Value $128.92m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.90
P/S ratio (TTM) P/S ratio 2.30
P/B ratio (TTM) P/B ratio 1.42
Revenue growth (TTM) Revenue growth 15.43%
Revenue (TTM) Revenue $143.68m
EBIT (operating result TTM) EBIT $-82.08m
Free Cash Flow (TTM) Free Cash Flow $-89.87m
Cash position $216.95m
EPS (TTM) EPS $-2.52
P/E forward negative
P/S forward 3.58
EV/Sales forward 1.39
Short interest 29.67%
Show more

Is Arcturus Therapeutics Ltd a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Arcturus Therapeutics Ltd Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Arcturus Therapeutics Ltd forecast:

11x Buy
100%

Analyst Opinions

11 Analysts have issued a Arcturus Therapeutics Ltd forecast:

Buy
100%

Financial data from Arcturus Therapeutics Ltd

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
144 144
15% 15%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 49 49
9% 9%
34%
- Research and Development Expense 176 176
9% 9%
123%
-79 -79
35% 35%
-55%
- Depreciation and Amortization 3.44 3.44
5% 5%
2%
EBIT (Operating Income) EBIT -82 -82
33% 33%
-57%
Net Profit -68 -68
36% 36%
-47%

In millions USD.

Don't miss a Thing! We will send you all news about Arcturus Therapeutics Ltd directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Arcturus Therapeutics Ltd Stock News

Neutral
Seeking Alpha
12 days ago
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT ) Q1 2025 Earnings Conference Call May 12, 2025 4:30 PM ET Company Participants Neda Safarzadeh - Vice President, Head of Investor Relations, Public Relations and Marketing Joe Payne - President and Chief Executive Officer Andy Sassine - Chief Financial Officer Pad Chivukula - Chief Scientific Officer and Chief Operating Officer Conference Call P...
Neutral
Business Wire
13 days ago
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced its financial results for the first quarter ended March 31, 2025, and provided corpo...
Neutral
Business Wire
about one month ago
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended March 31, 2025 afte...
More Arcturus Therapeutics Ltd News

Company Profile

Arcturus Therapeutics Holdings, Inc. engages in the research and development of medical applications for the nucleic acid-focused technology. The firm develops RNA therapeutics which focuses on the treatment of liver and respiratory diseases. Its pipeline include LUNAR-OTC and LUNAR CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Head office Israel
CEO Joseph Payne
Employees 175
Founded 2013
Website arcturusrx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today